{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:04:32Z","timestamp":1787771072618,"version":"build-2784847793"},"reference-count":0,"publisher":"American Diabetes Association","issue":"2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1995,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To investigate the effects of long-term high-dose oral magnesium (Mg) therapy (30 mmol\/day) in patients with type II diabetes. Low plasma magnesium levels have been reported in type II diabetes and are associated with insulin resistance and diabetic late complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Forty patients with type II diabetes and hypomagnesemia were observed in a randomized double-blind placebo-controlled trial for 3 months (body mass index: 28 \u00b1 4 kg\/m2; HbA1c: 7.4 \u00b1 0.8%). Plasma and urine magnesium and metabolic control parameters were determined, and side effects were considered, especially with regard to patients' compliance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>A significant increase in plasma magnesium levels was observed after 3 months of treatment (Mg: 0.73 \u00b1 0.8 vs. 0.81 \u00b10.1 mmol\/1), reaching magnesium levels of the control group (0.88 \u00b1 0.8 mmol\/1; NS); metabolic control, however, was not altered (HbA1c: 7.2 \u00b1 0.7 vs. 7.4 \u00b1 0.9%). Six months after the end of the trial, plasma magnesium declined to pretreatment levels (Mg: 0.73 \u00b1 0.07 mmol\/1). The prevalence of side effects was high at the beginning and was reduced significantly during treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>We conclude that oral magnesium replacement therapy corrects hypomagnesemia after a minimum treatment period of 3 months. These observations might be important for the prevention of diabetic late complications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/diacare.18.2.188","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"188-192","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":71,"title":["Hypomagnesemia in Type II Diabetes: Effect of a 3-Month Replacement Therapy"],"prefix":"10.2337","volume":"18","author":[{"given":"Nicole L","family":"Eibl","sequence":"first","affiliation":[{"name":"First Department of Medicine, Rudolfstiftung Hospital\u2008Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Kopp","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Rudolfstiftung Hospital\u2008Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga R","family":"Nowak","sequence":"additional","affiliation":[{"name":"Central Laboratory, Rudolfstiftung Hospital\u2008Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph J","family":"Schnack","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Rudolfstiftung Hospital\u2008Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre G","family":"Hopmeier","sequence":"additional","affiliation":[{"name":"Central Laboratory, Rudolfstiftung Hospital\u2008Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guntram","family":"Schernthaner","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Rudolfstiftung Hospital\u2008Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/18\/2\/188\/443483\/18-2-188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/18\/2\/188\/443483\/18-2-188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T12:47:44Z","timestamp":1647089264000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/18\/2\/188\/19159\/Hypomagnesemia-in-Type-II-Diabetes-Effect-of-a-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,2,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1995,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.18.2.188","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,2,1]]}}}